THE US Food and Drug Administration (FDA) has approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
This is the first drug approved by the FDA for PPMS and is in an intravenous infusion form to be administered by a health care professional.
The above article was sent to subscribers in Pharmacy Daily's issue from 31 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Mar 17
